Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial” Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee Clinical and Molecular Hepatology.2025; 31(1): e81. CrossRef
Advances and challenges in immunotherapy and molecular imaging for hepatocellular carcinoma Tu Haibin Discover Oncology.2025;[Epub] CrossRef
In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE had been pointlessly carried out repeatedly. It was in the early 2010s that the concept of TACE refractory was advocated. Two retrospective studies from Japan indicated that conversion from TACE to sorafenib the day after patients were deemed as TACE refractory improved overall survival compared with continued TACE, according to the definition by the Japan Society of Hepatology. Nowadays, phase 3 trials have shown clinical benefits of several novel molecular target agents. Compared with the era of sorafenib, sequential treatments with these molecular target agents have gradually prolonged patients’ survival and have become major strategies in patients with HCC. Taking these together, conversion from TACE to systemic therapies at the time of TACE refractory, compared with before, may have a greater impact on survival and may be considered deeper in the decisions-making process in patients with unresectable HCC who are candidate for TACE. Up-to-date information on the concept of TACE refractory is summarized in this review. We believe that the survival of patients with unresectable HCC without both macrovascular invasion and extrahepatic metastasis may be dramatically improved by optimal timing of TACE refractory and switching to systemic therapies.
Citations
Citations to this article as recorded by
Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib Hideki Iwamoto, Shigeo Shimose, Hironori Koga, Takumi Kawaguchi Journal of Liver Cancer.2026; 26(1): 83. CrossRef
AI models based on gadoxetic acid–enhanced MRI to predict treatment response and prognosis after TACE in hepatocellular carcinoma Jiangqin Ma, Linghong Kong, Wenlong Song, Xin Li, Xiaojing He, Xi Liu, Dajing Guo, Yangyang Liu Frontiers in Oncology.2026;[Epub] CrossRef
Sequential Use of Systemic Therapy With Locoregional Therapy for Hepatocellular Carcinoma in Japan: Analyses of Real‐World Data Based on a Health Claims Database Junichi Shindoh, Sachiyo Shirakawa, Ikumi Takashima, Daisuke Kawai, Kenichiro Nishida, Hiroshi Kitagawa Cancer Medicine.2026;[Epub] CrossRef
Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis Wei Lu, Zhiyuan Li, Chen Pan, Bingliang Chen, Gang Zhang, Zhiming Yang, Jingcheng Hao Journal of Cancer Research and Clinical Oncology.2025;[Epub] CrossRef
Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) Hang Yuan, Zhen Li, Guang-Shao Cao, Fei Xu, Gang Wu, Peng-Xu Ding, Qiu-Liang Wei, Zu-Kuan Chang, Cheng Xing, Huan-Zhang Niu, Jun Yin, Quan-Jun Yao, Lin Zheng, Jin-Cheng Xiao, Cheng-Shi Chen, Hong-Tao Cheng, Deng-Wei Zong, Wei-Li Xia, Xiang Geng, Xiao-Hui Frontiers in Oncology.2025;[Epub] CrossRef
Landscape and prognostic values of lymphocytes in patients with hepatocellular carcinoma undergoing transarterial embolization Rui-dong Zhao, Ding-jie Liu, Jia-wei Li, Yong Wang, Jun-hao Lin, Yi-tian Zhang, Yong Li, Mei-xiao Zhan, Zhi-nan Yin, Li-gong Lu, Bing Liu Journal of Leukocyte Biology.2024; 116(1): 186. CrossRef
Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis Jiahui Yu, Duan Yan, Song Wei, Linfeng Yang, Pengsheng Yi Oncology Letters.2024;[Epub] CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization Jiachen Xu, Yu Yin, Jun Yang, Li Chen, Zhi Li, Jian Shen, Wansheng Wang, Caifang Ni Frontiers in Oncology.2023;[Epub] CrossRef
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maj Cancer Treatment Reviews.2023; 115: 102526. CrossRef
Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients Sung Won Chung, Heejin Cho, Hyunjae Shin, Jeayeon Park, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Myungsu Lee, Yoon Jun Kim, Jin Chul Paeng, Jung-Hwan Yoon, Jin Wook Chung, Jeong-Hoon Lee, Hyo-Cheol Kim Frontiers in Oncology.2023;[Epub] CrossRef
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review Brandon M. Meyers, Jennifer J. Knox, David M. Liu, Deanna McLeod, Ravi Ramjeesingh, Vincent C. Tam, Howard J. Lim Cancer Treatment Reviews.2023; 118: 102584. CrossRef
Transarterial chemoembolization for advanced hepatocellular carcinoma without macrovascular invasion or extrahepatic metastasis: analysis of factors prognostic of clinical outcomes Ji Hoon Kim, Jin Hyoung Kim, Hyun-Ki Yoon, Gi-Young Ko, Ji Hoon Shin, Dong Il Gwon, Heung-Kyu Ko, Hee Ho Chu, Seong Ho Kim, Gun Ha Kim, Yonghun Kim, Shakir Aljerdah Frontiers in Oncology.2023;[Epub] CrossRef
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
Double closed loop small bowel obstruction due to right diaphragmatic hernia after transcatheter arterial chemoembolization and microwave ablation for hepatocellular carcinoma Noppachai Siranart, Manichaya Sukonpatip, Walit Sowalertrat Clinical Journal of Gastroenterology.2023; 16(5): 673. CrossRef
Predictive Role of Pretreatment Circulating miR-221 in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Nutcha Pinjaroen, Piyawan Chailapakul, Supachaya Sriphoosanaphan, Natthaya Chuaypen, Pisit Tangkijvanich Diagnostics.2023; 13(17): 2794. CrossRef
A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma Dandan Wang, Linhan Zhang, Zhongqi Sun, Huijie Jiang, Jinfeng Zhang European Journal of Radiology.2023; 167: 111086. CrossRef
Role of Immunological Cells in Hepatocellular Carcinoma Disease and Associated Pathways Ram Aasarey, Kajal Yadav, Brijendra Kumar Kashyap, Sarit Prabha, Pramod Kumar, Anil Kumar, Janne Ruokolainen, Kavindra Kumar Kesari ACS Pharmacology & Translational Science.2023; 6(12): 1801. CrossRef
Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study Ya Gao, Haohao Lu, Zhifan Xiong Frontiers in Oncology.2023;[Epub] CrossRef
Diaphragmatic perforation after transcatheter arterial chemoembolization of hepatocellular carcinoma via inferior phrenic artery: a case report Ji Soo Kim, Hyoung Nam Lee, Woong Hee Lee, Suk Hyun Bae BMC Gastroenterology.2022;[Epub] CrossRef
Successful Combined S Systemic-Regional Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma: Report of Two Cases P. G. Tarazov, T. I. Kagacheva, A. A. Polikarpov, A. V. Moiseenko Journal of oncology: diagnostic radiology and radiotherapy.2022; 5(1): 83. CrossRef
Nationwide database analysis of insomnia, depression, and sleeping pill prescriptions in hepatocellular carcinoma patients Keishi Akada, Noriyuki Koyama, Yuji Miura, Ken Aoshima Current Medical Research and Opinion.2022; 38(8): 1333. CrossRef
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma Pil Soo Sung Clinical and Molecular Hepatology.2022; 28(3): 333. CrossRef
Sequential treatment after transcatheter arterial chemoembolization for patients with single large hepatocellular carcinoma Po‐Heng Chuang, Sheng‐Nan Lu Advances in Digestive Medicine.2022; 9(3): 141. CrossRef
Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma Wei-Li Xia, Shi-Jun Xu, Yuan Guo, Xiao-Hui Zhao, Hong-Tao Hu, Yan Zhao, Quan-Jun Yao, Lin Zheng, Dong-Yang Zhang, Chen-Yang Guo, Wei-Jun Fan, Hai-Liang Li Frontiers in Oncology.2022;[Epub] CrossRef
Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon Frontiers in Oncology.2022;[Epub] CrossRef
Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(12): 1031. CrossRef
Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities Cyrill Wehling, Michael T. Dill, Alexander Olkus, Christoph Springfeld, De-Hua Chang, Patrick Naumann, Thomas Longerich, Clemens Kratochwil, Arianeb Mehrabi, Uta Merle, Jan Pfeiffenberger, Christian Rupp, Karl Heinz Weiss, Markus Mieth Journal of Cancer Research and Clinical Oncology.2021; 147(8): 2471. CrossRef
Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura Clinical and Molecular Hepatology.2021; 27(4): 616. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis Yanmei Dai, Huijie Jiang, Hao Jiang, Sheng Zhao, Xu Zeng, Ran Sun, Ruoshui Zheng Translational Oncology.2021; 14(12): 101238. CrossRef
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Cancers.2021; 14(1): 67. CrossRef
Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report Satoshi Komiyama, Kazushi Numata, Katsuaki Ogushi, Makoto Chuma, Reiko Tanaka, Sawako Chiba, Masako Otani, Yoshiaki Inayama, Masayuki Nakano, Shin Maeda Diagnostics.2021; 11(8): 1394. CrossRef
A case of sorafenib-induced severe thrombocytopenia during treatment of unresectable hepatocellular carcinoma Xiaoying Quan, Xiaoyan Chen, Lei Lei, Chunzhi Wu, Xiaoli Jia, Bin Ye Oncology and Translational Medicine.2021; 7(5): 235. CrossRef
Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection Pil Soo Sung, Jeong Won Jang, Jaejun Lee, Soon Kyu Lee, Hae Lim Lee, Hyun Yang, Hee Chul Nam, Sung Won Lee, Si Hyun Bae, Jong Young Choi, Nam Ik Han, Seung Kew Yoon Frontiers in Oncology.2020;[Epub] CrossRef
Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization Zheng Guo, Jing Wang, Li Li, Rong Liu, Jin Fang, Bin Tie World Journal of Clinical Cases.2020; 8(16): 3493. CrossRef
Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Yasuharu Imai, Masahide Oshita, Kazuyoshi Ohkawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara Hepatology Research.2020; 50(11): 1275. CrossRef
Effect of urea cream on sorafenib-associated hand–foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study Young-Sun Lee, Young K. Jung, Ji H. Kim, Sung B. Cho, Do Y. Kim, Moon Y. Kim, Hyung J. Kim, Yeon S. Seo, Ki T. Yoon, Young M. Hong, Jeong-Hoon Lee, Hyun W. Lee, Hyung J. Yim, Byoung K. Jang, Eun S. Jang, Jae Y. Jang, Sang Y. Hwang European Journal of Cancer.2020; 140: 19. CrossRef
Research Progress of TACE Combined with Sorafenib in the Treatment of HCC 欣 姚 Asian Case Reports in Oncology.2020; 09(04): 17. CrossRef
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma Young Chang, Soung Won Jeong, Jae Young Jang, Yong Jae Kim International Journal of Molecular Sciences.2020; 21(21): 8165. CrossRef
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy Pil Soo Sung, Moon Hyung Choi, Hyun Yang, Soon Kyu Lee, Ho Jong Chun, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Joon-Il Choi, Young Joon Lee, Si Hyun Bae Frontiers in Oncology.2020;[Epub] CrossRef
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC Jaejun Lee, Pil Soo Sung, Hyun Yang, Soon Kyu Lee, Hee Chul Nam, Sun Hong Yoo, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon Journal of Clinical Medicine.2020; 9(12): 4121. CrossRef
First
Prev
